Background
Obesity is an increasing health problem in developed countries, where the prevalence of Helicobacter pylori infection is decreasing. Recent studies suggested colonization of the stomach by H pylori might affect gastric expression of appetite- and satiety-related hormone and patients cured of H pylori infection gained weight. It was hypothesized that H pylori could be a contributing pathogenic factor in childhood and adult obesity.
Methods
To determine whether H pylori infection is linked to obesity, a case-control study composed of 414 patients with morbid obesity (a body mass index [calculated as weight in kilograms divided by the square of height in meters] of ≥35 with serious comorbidity or a body mass index of ≥40) and 683 control subjects (a body mass index of <25) with a comparable socioeconomic status was conducted. Immunoglobulin G antibodies against H pylori were measured from frozen serum samples by an enzyme-linked immunosorbent assay. Logistic regression was used to calculate the odds ratio (OR) and 95% confidence interval (CI).
Results
The overall seropositivity was significantly lower in obese patients (181 [43.7%] of 414) than controls (410 [60.0%] of 683) (OR, 0.50; 95% CI, 0.39-0.65; P<.001). Differences in the estimated risk of the presence of H pylori were more pronounced in younger age groups, with ORs of 0.32 (95% CI, 0.10-1.00; P = .05) in those aged 10 to 19 years, 0.55 (95% CI, 0.34-0.89; P = .01) in those aged 20 to 29 years, 0.49 (95% CI, 0.30-0.80; P = .007) in those aged 30 to 39 years, and 0.58 (95% CI, 0.33-1.00; P = .05) in those aged 40 years or older.
Conclusions
Our data indicated an inverse relationship between morbid obesity and H pylori seropositivity. These findings raise the hypothesis that a lack of H pylori infection, especially during childhood, might enhance the risk of the development of morbid obesity.
Obesity has become a major public health problem of global significance. Health conditions caused or exacerbated by obesity include hypertension, diabetes mellitus, sleep apnea, obesity-related hypoventilation, back and joint problems, cardiovascular disease, and gastroesophageal reflux disease. The body mass index (BMI) (calculated as weight in kilograms divided by the square of height in meters) is the most commonly accepted measurement for obesity. A BMI exceeding 25 is considered overweight, while obesity is defined as a BMI of 30 or more. A BMI of 35 or more with serious comorbidity or a BMI of 40 or more is considered morbid obesity.1 The incidence of obesity has increased rapidly during the past 2 decades. This increase had been most dramatic in affluent countries. The factors underlying this increase are largely unknown. Although multiple studies show that the genetic contribution is significant, our genes have not changed appreciably during this period. An increasing obesigenic lifestyle of excessive caloric intake and decreased physical activity are assumed to play a central role in this epidemiologic trend.2 Whether there are other environmental factors likely to explain the epidemic of obesity remains to be elucidated.
Helicobacter pylori is a gram-negative bacillus. It was estimated that half of the world’s adult population harbors H pylori in their stomach. In developing countries, the infectious process occurs early and reaches 60% to 80% in adulthood. The annual incidence of H pylori acquisition by adults is much lower in developed countries. The increase by age largely reflects a birth cohort phenomenon.3Helicobacter pylori is the main causative factor of chronic gastritis. Epidemiologic studies have consistently linked H pylori infection to peptic ulcer and gastric malignancies.4 The diverse outcomes of H pylori infection are ascribed to the difference in extent and severity of gastritis, which leads to variation in the amount of gastric secretion and creates a permissive luminal milieu for disease to develop.5 Recently, the spectrum of H pylori–related diseases has expanded to include gastroesophageal reflux disease and obesity. The parallel epidemic of gastroesophageal reflux disease and obesity combined with decreasing H pylori infection in western countries suggests H pylori might play a protective role in the development of obesity and gastroesophageal reflux disease.6,7 Based on the findings that eradication of H pylori could influence the dynamic of ghrelin and increase body weight,8-11 Blaser and Atherton12 proposed that H pylori infection might influence food intake and calorie homeostasis through defective signaling of appetite-related hormone in the stomach. A possible inverse relationship between exposure to H pylori and the occurrence of obesity has been further addressed in studies of morbid obesity.13-15 Preliminary data by histological examinations have shown that the infection rate of H pylori in these patients ranged from 24% to 38%.13-15 However, controversial results existed, and whether H pylori infection plays a role in childhood and adult adiposity remains to be determined.12-18
Taiwan is a newly industrialized country where the incidence of obesity is accelerating and H pylori infection is prevalent.19,20 A recent mass screening program even showed the increase of childhood diabetes mellitus on this island is due to obesity.21 To clarify the relationship between obesity and H pylori infection, we investigated, in a case-control study, the seroprevalences of H pylori among patients with morbid obesity and control subjects with a normal weight.
Studied concomitantly in a random order,22 we selected consecutive patients affected by morbid obesity between January 1, 2001, and December 31, 2003. A case was defined as a patient with a BMI of 35 or more with a serious comorbidity or with a BMI of 40 or more who was admitted to En-Chu Kong Hospital for evaluation of the possibility of weight reduction surgery. Blood samples for a prospective investigation of the effect of surgery on these patients were collected. Finally, 414 eligible patients (115 men and 299 women; mean ± SD age, 31.9 ± 9.2 years) were enrolled. In the same period, we also enrolled controls from healthy subjects with a BMI of less than 25 who underwent a health checkup at the same center. A total of 683 controls (337 men and 346 women; mean ± SD age, 32.3 ± 9.5 years) fulfilling the criteria were selected. Cases and controls were from the geographical area of northern Taiwan and had a similar socioeconomic status, judged by work type and level of instruction. Written informed consent was obtained from each participant, and the ethical committee of the hospital approved the study.
Venous blood samples were obtained from the patients and controls after an overnight fast. Serum was separated in a cold centrifuge at 2000 rpm for 10 minutes and was stored in a deep freezer at −20°C until studied concomitantly in a random order. The fasting glucose concentration was determined using an enzymatic colorimetric method (Sigma Chemical, St Louis, Mo). Serum insulin levels were measured by an immune luminescence assay (Access; Beckman Coulter, Brea, Calif). Insulin resistance was estimated by the homeostasis model of assessment based on the following formula: [fasting insulin level (measured in micro–international units per milliliter) × fasting glucose level (measured in milligrams per milliliter)]/22.5. High-sensitivity C-reactive protein was measured using immunonephelometry (Nephelometer Analyzer II; Dade Behring, Deerfield, Ill). A commercially available enzyme-linked immunosorbent assay kit (IBL, Hamburg, Germany) with reported sensitivity and specificity of more than 95% was used to investigate the prevalence of H pylori infection. All assays were performed in duplicate and interpreted by a single laboratory investigator (M.-S.W.) unaware of sample status to avoid the possibility of interobserver variability.
All data for cases and controls were computerized, and statistical analysis was performed using a commercially available software program (SPSS, version 11.0; SPSS Inc, Chicago, Ill). χ2 And t tests were used for categorical and continuous data, respectively. Nonparametric tests (Kruskal-Wallis) have been used for cases of nonnormality. The strength of association between H pylori and sex or age was measured by binary logistic regression to estimate the odds ratio and 95% confidence interval (CI).
The seroprevalence of H pylori was 43.7% (181/414) for cases of morbid obesity and 60.0% (410/683) for controls (odds ratio, 0.50; 95% CI, 0.39-0.65; P<.001). The distributions of seropositivity of H pylori with respect to age and sex in cases and controls are summarized in Table 1. Differences in the estimated risk of the presence of H pylori were more pronounced in younger age groups, with odds ratios of 0.32 (95% CI, 0.10-1.00; P = .05) in those aged 10 to 19 years, 0.55 (95% CI, 0.34-0.89; P = .01) in those aged 20 to 29 years, 0.49 (95% CI, 0.30-0.80; P = .007) in those aged 30 to 39 years, and 0.58 (95% CI, 0.33-1.00; P = .05) in those aged 40 years or older. On the other hand, sex has no effect on the distribution of H pylori seropositivity. The clinical, demographic, and metabolic variables were further compared between H pylori–positive and H pylori–negative patients with morbid obesity. No difference in BMI, age, sex, white blood cell count, hemoglobin concentration, high-sensitivity C-reactive protein level, glycosylated hemoglobin level, and homeostasis model of assessment value was observed between these 2 groups (Table 2).
Increasing attention has recently been paid to the role of H pylori in the pathogenesis of nutritional problems and obesity.8-18 The results of this case-control study show a statistically significant inverse relationship between morbid obesity and H pylori seropositivity. Of special interest is that the younger the age, the greater the influence of H pylori. These findings raise the hypothesis that a lack of H pylori infection, particularly during childhood, might favor the development of obesity.
The prevalence of H pylori infection is related to several confounding factors, such as age and socioeconomic status.20 There is evidence of a decreased seroprevalence of H pylori in developed countries during recent decades.3,4 The decrease in H pylori seroprevalence seems to coincide with the increase in the incidence of obesity. Previous studies19,20 in Taiwan indicated that the seropositivity of H pylori in the general population varied from 54% to 63% and the incidence of obesity has increased to the level of developed countries. In the present study, the seroprevalence of H pylori in the control group was within the reported range.20 Furthermore, the marked decrease in seroprevalence of H pylori with decreasing age in morbidly obese patients supports the notion that populations with a low prevalence of H pylori have more obese individuals.12 However, certain limitations were noted in interpreting our observations. Although both groups were said to be of the same socioeconomic status, it is likely that a more sensitive assessment would have found among the controls more individuals from larger sibships, who had grown up in more crowded homes. Effectively, thin people are more likely to be of lower socioeconomic status than age-matched obese people.23 In addition, we had no data regarding exposure to antibiotics between the 2 groups.
Prior studies13-18 have not uniformly demonstrated a clear association of H pylori with obesity. Scapa et al13 first recognized that the incidence of H pylori in stomachs of morbidly obese patients was low: 26.7% in 15 obese patients by culture and biopsy urease test results. Renshaw et al14 and Ramaswamy et al15 have documented that 38% and 24% of patients undergoing surgery for morbid obesity have evidence of H pylori by histological examination result, respectively. Consistent with these earlier studies, the seroprevalence of H pylori in our large cohort of morbidly obese patients was relatively lower (43.7%) compared with our controls. On the other hand, several studies16-18 with a non–case-control design have described the lack of any difference in prevalence of H pylori with respect to body weight. Kawano et al16 reported that H pylori infection was not related to BMI in asymptomatic subjects. Kyriazanos et al17 found that the incidence of H pylori is not increased in obese people. Perdichizzi et al18 even showed H pylori infection tended to increase in hyperglycemic obese subjects. Collectively, the major controversy from different studies seemed to arise from method. Small sample sizes, different definition of obesity and selection of patients, various detecting methods of H pylori infection, no control group, and lack of consideration of confounding factors are among the reasons to explain the discrepant results. Further large-scale prospective studies of comparable subjects with full consideration of the confounding factors are warranted to definitely establish the protective role of H pylori in morbidly obese patients.
It is not possible to deduce from our study the causal relationship between H pylori infection and obesity. The mechanisms underlying the inverse association have remained obscure, but several potential interactions are operative between H pylori and obesity. Blaser and Atherton12 proposed a fascinating pathogenic role of H pylori in obesity in a recent review. They assumed that H pylori–induced persistent and uncontrolled gastric inflammation would lead to dysregulation of appetite and calorie homeostasis through its effect on the expression of gut hormones such as ghrelin.8-11 Therefore, individuals exposed to H pylori in early childhood are prone to have a decreased appetite and food intake due to defective signaling of appetite- and satiety-related hormone in the stomach. Moreover, the coexisting dyspepsia would exaggerate the poor nutritional status in H pylori–positive subjects and they, thus, tended to be thinner than their H pylori–negative counterparts in adulthood. Our data, as far as the greater difference of H pylori seropositivity in younger age groups, comply with this hypothesis. In our study, we did not investigate ghrelin levels. This issue has recently been addressed in animal and human studies.8-11 Experimental work by Suzuki et al9 demonstrated that expression of ghrelin levels in the stomach was significantly decreased in Mongolian gerbils colonized by H pylori. Nwokolo et al8 reported that plasma ghrelin increased profoundly following eradication of H pylori. Tatsuguchi et al11 have also shown gastric tissue ghrelin concentration increased significantly after H pylori eradication. Furthermore, Furuta et al10 have documented that patients cured of H pylori gained weight. Taken together, these studies have provided evidence that nutritional status and gastric and plasma ghrelin dynamics are altered in response to H pylori infection. However, evidence conflicts as to whether metabolic variables and levels of ghrelin were influenced by H pylori infection.24-26 Candelli et al25 showed that H pylori infection and cytotoxin-associated gene A–positive strains do not affect metabolic control in patients with type 1 diabetes mellitus. Gokcel et al26 also reported that H pylori has no effect on plasma ghrelin concentration. Both of these studies were cross-sectional. Helicobacter pylori infection in early childhood may be a key issue, and a long induction time seems to be required because ghrelin is a long-term regulator of body weight rather than a short-term meal-related orexigenic signal in humans.24 Therefore, further in-depth studies in this field are mandatory to clarify the relationship and mechanisms between H pylori and the development of obesity.
In conclusion, our data indicated an inverse relationship between morbid obesity and H pylori seropositivity. These findings raise the hypothesis that a lack of H pylori infection, especially during childhood, might favor the development of morbid obesity. Further large-scale, prospective, epidemiologic studies with full consideration of confounding factors and in-depth mechanistic investigations are warranted to elucidate whether H pylori infection could be a contributing pathogenic factor in childhood and adult obesity.
Correspondence: Jaw-Town Lin, MD, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, Taiwan (jawtown@ha.mc.ntu.edu.tw).
Accepted for Publication: February 20, 2005.
Financial Disclosure: None.
Funding/Support: This study was supported by grants NSC2314-B002-122, NSC2314-B002-123, and NSC2314-B002-124 from the National Science Council, Taipei, Taiwan.
1.MacDonald
KG
Jr Overview of the epidemiology of obesity and the early history of procedures to remedy morbid obesity.
Arch Surg 2003;138357- 360
PubMedGoogle ScholarCrossref 4.Perez-Perez
GIRothenbacher
DBrenner
H Epidemiology of
Helicobacter pylori infection.
Helicobacter 2004;9
((suppl 1))
1- 6
PubMedGoogle ScholarCrossref 5.Ernst
PBGold
BD The disease spectrum of
Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer.
Annu Rev Microbiol 2000;54615- 640
PubMedGoogle ScholarCrossref 6.Raghunath
AHungin
APWooff
DChilds
S Prevalence of
Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review.
BMJ 2003;326737
PubMedGoogle ScholarCrossref 7.Murray
LJohnston
BLane
A
et al. Relationship between body mass and gastroesophageal reflux symptoms: the Bristol
Helicobacter Project.
Int J Epidemiol 2003;32645- 650
PubMedGoogle ScholarCrossref 9.Suzuki
HMasaoka
THosoda
H
et al.
Helicobacter pylori infection modifies gastric and plasma ghrelin dynamics in Mongolian gerbils.
Gut 2004;53187- 193
PubMedGoogle ScholarCrossref 10.Furuta
TShirai
NXiao
FTakashima
MHanai
H Effect of
Helicobacter pylori infection and its eradication on nutrition.
Aliment Pharmacol Ther 2002;16799- 806
PubMedGoogle ScholarCrossref 11.Tatsuguchi
AMiyake
KGudis
K
et al. Effect of
Helicobacter pylori infection on ghrelin expression in human gastric mucosa.
Am J Gastroenterol 2004;992121- 2127
PubMedGoogle ScholarCrossref 13.Scapa
EBoldur
IIGluskin
JBroide
EBogokowsky
HEshchar
J
Helicobacter pylori before and after gastric reduction for morbid obesity.
Obes Surg 1992;2371- 374
PubMedGoogle ScholarCrossref 14.Renshaw
AARabaza
JRGonzalez
AMVerdeja
JC
Helicobacter pylori infection in patients undergoing gastric bypass surgery for morbid obesity.
Obes Surg 2001;11281- 283
PubMedGoogle ScholarCrossref 15.Ramaswamy
ALin
ERamshaw
BJSmith
CD Early effects of
Helicobacter pylori infection in patients undergoing bariatric surgery.
Arch Surg 2004;1391094- 1096
PubMedGoogle ScholarCrossref 16.Kawano
SKawahara
ANakai
RFu
HYTsuji
STsuji
M
Helicobacter pylori infection does not affect serum leptin concentration and body mass index.
J Gastroenterol 2001;36579- 580
PubMedGoogle ScholarCrossref 17.Kyriazanos
IDSfiniadakis
IGizaris
V
et al. The incidence of
Helicobacter pylori infection is not increased among obese young individuals in Greece.
J Clin Gastroenterol 2002;34541- 546
PubMedGoogle ScholarCrossref 18.Perdichizzi
GBottari
MPallio
SFera
MTCarbone
MBarresi
G Gastric infection by
Helicobacter pylori and antral gastritis in hyperglycemic obese and in diabetic subjects.
New Microbiol 1996;19149- 154
PubMedGoogle Scholar 19.Tsai
WLYang
CYLin
SFFang
FM Impact of obesity on medical problems and quality of life in Taiwan.
Am J Epidemiol 2004;160557- 565
PubMedGoogle ScholarCrossref 20.Lin
JTWang
LYWang
JTWang
THYang
CSChen
CJ A nested case-control study on the association between
Helicobacter pylori infection and gastric cancer in a cohort of 9775 men in Taiwan.
Anticancer Res 1995;15603- 606
PubMedGoogle Scholar 21.Wei
JNSung
FCLin
CCLin
RSChiang
CCChuang
LM National surveillance for type 2 diabetes mellitus in Taiwanese children.
JAMA 2003;2901345- 1350
PubMedGoogle ScholarCrossref 23.EUROGAST Study Group, Epidemiology of and risk factors for
Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations.
Gut 1993;341672- 1676
PubMedGoogle ScholarCrossref 24.Cummings
DEWeigle
DSFrayo
RS
et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery.
N Engl J Med 2002;3461623- 1630
PubMedGoogle ScholarCrossref 25.Candelli
MRigante
DMarietti
G
et al.
Helicobacter pylori, gastrointestinal symptoms, and metabolic control in young type 1 diabetes mellitus patients.
Pediatrics 2003;111800- 803
PubMedGoogle ScholarCrossref 26.Gokcel
AGumurdulu
YKayaseluck
F
et al.
Helicobacter pylori has no effect on plasma ghrelin levels.
Eur J Endocrinol 2003;148423- 426
PubMedGoogle ScholarCrossref